Can eye tests track an inherited form of blindness?
NCT ID NCT07729982
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This study follows people with a genetic condition called OPA1-associated optic atrophy, which causes gradual vision loss. Researchers will use a battery of eye exams—including vision charts, contrast sensitivity, and retinal imaging—to see how the disease changes over time. The goal is to find reliable markers of disease severity and progression that could be used in future trials of potential treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify reliable ways to measure disease progression, paving the way for future treatment trials for this inherited cause of vision loss.
- What could go wrong
- This is an observational study, not a treatment trial, so it offers no direct benefit to participants. The findings may not translate into effective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will be recruited from the inherited retinal disease and ophthalmogenetics clinic of the Department of Ophthalmology, University Hospital, Ludwig-Maximilians-Universität München, Germany. The study population consists of patients followed at this tertiary referral center. Additional participants may be referred by genetic diagnostic centers or other physicians in Germany or abroad after molecular genetic testing and clinical suspicion of OPA1-related disease. Self-referral by patients with a previous diagnosis of OPA1-associated autosomal dominant optic atrophy is also accepted.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 6 years or older * Clinical diagnosis or clinical features consistent with optic atrophy * Molecular genetic confirmation of a pathogenic or likely pathogenic variant in the OPA1 gene * Ability of the participant, or the participant's parent or legal guardian, to understand the nature of the study and provide written informed consent (Participants are eligible for inclusion if all of the criteria mentioned above are met) Exclusion Criteria: \- Severe systemic disease or medical condition that, in the opinion of the investigator, would preclude participation in the study-related examinations
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPA1 gene mutation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Ophthalmology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München
RECRUITINGMunich, Bavaria, 80336, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.